Home › Funds › JACOBS LEVY EQUITY MANAGEMENT, INC › REGN
JACOBS LEVY EQUITY MANAGEMENT, INC position in REGN
REGENERON PHARMACEUTICALS · Health Care
JACOBS LEVY EQUITY MANAGEMENT, INC reported holding 256,503 shares of REGN (REGENERON PHARMACEUTICALS) in its Q2 2026 13F filing — a position valued at US$159.9M, representing 0.58% of its reported portfolio and ranking #36 among its reported holdings. JACOBS LEVY EQUITY MANAGEMENT, INC has disclosed REGN holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How JACOBS LEVY EQUITY MANAGEMENT, INC's REGN position evolved
JACOBS LEVY EQUITY MANAGEMENT, INC first disclosed a stake in REGN in Q4 2023 at 356 shares (US$313K). The position peaked in Q4 2025 at 264,991 shares, worth US$204.5M. Across 11 filings, JACOBS LEVY EQUITY MANAGEMENT, INC increased the stake 6 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 256,503 shares valued at US$159.9M — an increase of 42,343 shares quarter over quarter.. Notable position changes include a 3596% increase in Q2 2024 (shares were roughly flat over the following quarter), a 96% trim in Q4 2024 (shares fell 11% over the following quarter), a 31261% increase in Q2 2025 (shares rose 8% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 356 | $312.67K | New |
| Q1 2024 | 362 | $348.42K | Add |
| Q2 2024 | 13.38K | $14.06M | Add |
| Q3 2024 | 23.59K | $24.80M | Add |
| Q4 2024 | 847 | $603.34K | Reduce |
| Q1 2025 | 747 | $473.77K | Reduce |
| Q2 2025 | 234.27K | $122.99M | Add |
| Q3 2025 | 287.88K | $161.87M | Add |
| Q4 2025 | 264.99K | $204.54M | Reduce |
| Q1 2026 | 214.16K | $165.47M | Reduce |
| Q2 2026 | 256.50K | $159.94M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About REGN and 13F data
REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 31 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), LOOMIS SAYLES & CO L P (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding REGN
- Dodge & Cox 4.87M sh · $3.04B · Q2 2026
- DODGE & COX 4.87M sh · $3.04B · Q2 2026
- LOOMIS SAYLES & CO L P 1.86M sh · $1.16B · Q2 2026
More on JACOBS LEVY EQUITY MANAGEMENT, INC
FAQ
How long has JACOBS LEVY EQUITY MANAGEMENT, INC held REGN?
JACOBS LEVY EQUITY MANAGEMENT, INC has disclosed REGN holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
What is JACOBS LEVY EQUITY MANAGEMENT, INC's current position in REGN?
As of Q2 2026, JACOBS LEVY EQUITY MANAGEMENT, INC holds 256.50K shares of REGN (REGENERON PHARMACEUTICALS), valued at $159.94M, representing 0.58% of its reported portfolio and ranking #36.
Has JACOBS LEVY EQUITY MANAGEMENT, INC been buying or selling REGN?
In the latest 13F filing (Q2 2026), JACOBS LEVY EQUITY MANAGEMENT, INC increased its position in REGN. The position peaked in Q4 2025 at 264.99K shares.
Which other funds hold REGN?
Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, LOOMIS SAYLES & CO L P, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.